# IVC Filters: Indications, Retrieval, and Complications

## Overview

Inferior vena cava (IVC) filters are metallic or synthetic devices implanted in the infrarenal segment of the IVC to trap emboli and prevent pulmonary embolism (PE). In the United States, over 250,000 filters are placed annually, a rate significantly higher than in Europe. The FDA issued safety communications in 2010 and updated them in 2014, recommending retrieval of these filters once the indication for filtration resolves. Despite this, controversy persists regarding the overuse of IVC filters and the frequent failure to retrieve them when no longer necessary.

## Types of IVC Filters

### Retrievable (Optional) Filters

Retrievable filters are designed for both temporary and permanent use. They can be removed percutaneously when no longer needed. Common examples include the Gunther Tulip, Celect, Denali, Option Elite, and ALN filters. Currently, these "optional" filters account for more than 80% of filters placed. The term "optional" is preferred because all retrievable filters are FDA-approved for permanent implantation if necessary.

### Permanent Filters

Permanent filters cannot be removed once implanted. Examples include the Greenfield filter (made of titanium or stainless steel), TrapEase, VenaTech LP, and Bird's Nest filters. Their use is declining due to the availability of retrievable alternatives but they remain indicated when lifelong filtration is required.

### Temporary Filters (Tethered)

Temporary filters are attached to an external catheter and must be removed within a few days. Their use is very limited and has largely been abandoned in favor of retrievable designs.

<image>Comparison of different IVC filter designs including the Greenfield, Gunther Tulip, Denali, and Option Elite filters showing their structural configurations and deployed appearance</image>

## Indications

### Established (Strong) Indications

Strong indications for IVC filter placement include acute proximal deep vein thrombosis (DVT) or PE in patients with absolute contraindications to anticoagulation, such as active hemorrhage, recent major surgery, hemorrhagic stroke, or severe thrombocytopenia. Filters are also indicated for recurrent PE despite therapeutic anticoagulation and for complications of anticoagulation that necessitate its discontinuation in the setting of acute venous thromboembolism (VTE).

### Relative (Weaker) Indications

Relative indications include the presence of a large free-floating iliocaval thrombus, massive PE in patients with marginal hemodynamic reserve where further embolization could be fatal, prophylactic placement in high-risk trauma patients who cannot receive anticoagulation, perioperative protection in VTE patients undergoing surgery requiring anticoagulation interruption, and high-risk bariatric surgery patients, although the latter remains controversial and is not supported by strong evidence.

| Indication Category | Scenario | Strength of Evidence |
|--------------------|----------|---------------------|
| **Strong (Established)** | Acute proximal DVT/PE with absolute contraindication to anticoagulation | High |
| **Strong** | Recurrent PE despite therapeutic anticoagulation | High |
| **Strong** | Anticoagulation complication requiring discontinuation with active VTE | High |
| **Relative** | Large free-floating iliocaval thrombus | Moderate |
| **Relative** | Massive PE with marginal hemodynamic reserve | Moderate |
| **Relative** | Prophylaxis in high-risk trauma (cannot anticoagulate) | Low-Moderate |
| **Relative** | Perioperative protection in VTE patients requiring anticoagulation hold | Low |
| **NOT supported** | Primary VTE prophylaxis in medical patients | No benefit shown |
| **NOT supported** | Routine use in all trauma patients | No benefit shown |
| **NOT supported** | Bridge during anticoagulation interruption without active VTE | No benefit shown |

### Indications NOT Supported by Evidence

IVC filters are not supported for primary VTE prophylaxis in medical patients, routine use in all trauma patients, as a "bridge" during anticoagulation interruption without active VTE, or for prophylaxis in high-risk surgery patients without known VTE.

## Procedure

### Pre-Procedure Assessment

Before filter placement, the diameter of the IVC is measured, as most filters are rated for IVC diameters up to 28-30 mm. The location of the renal veins is identified because the filter is placed infrarenally to preserve renal venous outflow. Assessment for IVC anomalies such as duplicated IVC (occurring in 0.2-3% of individuals), left-sided IVC (0.2-0.5%), or circumaortic left renal vein is important. If the IVC diameter exceeds the filter's capacity, options include bilateral iliac vein filters or the Bird's Nest filter, which can accommodate diameters up to 40 mm.

### Access and Deployment

Filter placement typically occurs via the right common femoral vein or right internal jugular vein under fluoroscopic guidance with venacavography using contrast or CO2. The renal veins are identified, and the filter is deployed immediately below them. Intravascular ultrasound (IVUS) can be used as a radiation-free alternative in select cases. For critically ill patients, bedside placement using portable fluoroscopy or ultrasound guidance is feasible.

### Suprarenal Filter Placement

Suprarenal filter placement is indicated in cases of renal or gonadal vein thrombosis as a source of PE, IVC thrombus extending to the renal veins, or during pregnancy to avoid compression by the gravid uterus. This placement is generally well tolerated with minimal impact on renal function, and renal vein thrombosis caused by the filter is rare.

<image>Fluoroscopic image showing proper IVC filter deployment in the infrarenal position with cavogram identifying bilateral renal veins and confirming filter position</image>

## Retrieval

### Timing

The optimal time for filter retrieval is as soon as the indication for filtration resolves and anticoagulation can be safely resumed. Although most filters can be retrieved months to years after placement, the procedure becomes more difficult over time. The FDA recommends retrieval between 29 and 54 days when clinically feasible. Institutional tracking programs have been shown to improve retrieval rates.

### Standard Retrieval Technique

The most common approach for retrieval is via the right internal jugular vein. A snare catheter engages the filter's hook or retrieval feature, collapses the filter into a sheath, and removes it. Post-retrieval venography is performed to confirm the absence of IVC injury.

### Complex Retrieval Techniques (for Embedded/Tilted Filters)

For filters that are embedded or tilted, advanced techniques may be necessary. These include the use of rigid forceps such as Ensnare or Amplatz GooseNeck, loop snare combined with wire-through techniques, laser sheath dissection of endothelialized struts, excimer laser-assisted retrieval, and balloon displacement to realign tilted filters. Surgical retrieval via cavotomy is considered a last resort. Experienced centers report success rates exceeding 95%, even for chronically implanted filters.

### Retrieval Rates

Historically, national retrieval rates have been poor, with only 20-40% of retrievable filters removed. Dedicated retrieval programs employing automated tracking systems have improved rates to over 60-80%. Barriers to retrieval include loss to follow-up, persistent clinical need for filtration, and lack of referral for retrieval.

## Complications

### Procedural Complications

Procedural complications are uncommon but can include access site hematoma or thrombosis occurring in less than 1% of cases, filter malposition or deployment failure also under 1%, rare air embolism with careful technique, and caval perforation during deployment.

### In-Dwelling Complications

Filter thrombosis or IVC occlusion occurs in 2-10% of cases and may cause bilateral lower extremity swelling. Treatment involves anticoagulation and catheter-directed thrombolysis if the thrombosis is acute and symptomatic. Filter migration, either cranially or caudally, can rarely involve displacement to the heart or pulmonary arteries. This risk is higher with certain designs such as TrapEase and older generation filters. Cardiac migration may necessitate surgical or percutaneous extraction.

Strut fracture results from metallic fatigue leading to breakage of filter struts; fragments may embolize to the heart or lungs. These fractures are typically asymptomatic and discovered incidentally, but symptomatic embolized fragments require extraction. Caval penetration occurs when struts extend through the IVC wall into surrounding structures. While common on CT imaging—up to 40% of cases—symptomatic penetration is rare. Involvement of adjacent structures such as the aorta, duodenum, vertebral body, or ureter can occur. Rarely, symptomatic penetration manifests as pain, retroperitoneal hemorrhage, or aortoenteric fistula.

Recurrent PE despite filter placement occurs in 2-5% of patients and may result from embolization of filter clots, passage of small emboli through the filter interstices, or emboli originating from upper extremity DVT. Filters also increase the risk of DVT by acting as a nidus for thrombosis, with long-term DVT risk elevated as demonstrated in the PREPIC trial.

### Long-Term Concerns

The PREPIC trial showed that filters reduced PE at 12 days but increased DVT incidence at two years, with no mortality benefit at eight years when combined with anticoagulation. The PREPIC-2 trial compared retrievable filters plus anticoagulation versus anticoagulation alone for severe PE and found no benefit from the filter. Filters used without anticoagulation are associated with high rates of thrombotic complications.

<image>Radiographic images showing IVC filter complications including filter tilt, strut perforation through the IVC wall, and caval thrombosis with bilateral lower extremity swelling</image>

## Filter Tracking and Institutional Programs

Automated electronic medical record (EMR)-based tracking systems can flag patients with indwelling filters. Multidisciplinary filter clinics involving vascular surgery and interventional radiology facilitate standardized protocols, including clinical reassessment at 30, 60, and 90 days. At every encounter, clinicians should document whether the filter is still indicated and if anticoagulation can be resumed. Retrieval rates are tracked as a quality metric by the Centers for Medicare & Medicaid Services (CMS) and institutional quality programs.

## Clinical Pearls

The most effective IVC filter is one that is retrieved; therefore, planning for retrieval at the time of placement is essential. It is important to recognize that filters do not treat venous thromboembolism but only prevent pulmonary embolism; anticoagulation should be initiated as soon as it is safely possible. Most contraindications to anticoagulation are temporary and require frequent reassessment. An IVC filter is not a substitute for anticoagulation in patients who can be safely anticoagulated. The PREPIC and PREPIC-2 trials demonstrated no mortality benefit of filters when added to adequate anticoagulation. Overuse of IVC filters is a recognized quality problem, so every indication should be carefully questioned. Complex filter retrieval at experienced centers achieves success rates over 95%, so referral is preferable to leaving a filter permanently due to technical challenges. In trauma patients, pharmacologic prophylaxis should begin as soon as feasible; the filter serves as a bridge rather than definitive treatment.

## References
- Kaufman JA, et al. Society of Interventional Radiology clinical practice guideline for IVC filters. *J Vasc Interv Radiol*. 2020;31(2):218-232.
- PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of PE. *Circulation*. 2005;112(3):416-422.
- Mismetti P, et al. (PREPIC-2 trial) Effect of a retrievable IVC filter plus anticoagulation vs. anticoagulation alone on risk of recurrent PE. *JAMA*. 2015;313(16):1627-1635.
- Deso SE, et al. IVC filter complications and current evidence. *RadioGraphics*. 2016;36(7):2069-2092.
- FDA Safety Communication. Removing retrievable IVC filters: initial communication. 2010; updated 2014.